PAVmed Inc. (PAVM) reported Q1 2026 results, highlighting restructuring achievements and product portfolio advances. The stock rose 3.1% in premarket trading to $6.65. Despite a GAAP net loss of $1.1 million, the market reacted positively to strategic progress.
PAVmed completed a two-year restructuring, eliminating all convertible preferred stock and debt. This positions the company for future capital raises.
The company anticipates Medicare coverage for Lucid Diagnostics and advances in Veris Health. PAVmed plans to submit its Veris implantable physiological monitor for FDA approval by end of 2026.
CEO Dr. Lishan Aklog said: 'We successfully completed our restructuring, positioning PAVmed for future growth.'
